Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

Research output: Contribution to journal › Letter

Original language	English
Pages (from-to)	199-199
Number of pages	1
Journal	Medical Journal of Australia
Volume	182
Issue number	4
Publication status	Published - 21 Feb 2005

Cite this

@article{9f07b00335074b1fb0d330d996f909ae,

title = "Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions",

keywords = "RANDOMIZED CONTROLLED-TRIALS, ENDOTHELIAL FUNCTION, OSTEOARTHRITIS, INHIBITION, VALDECOXIB, EFFICACY, DISEASE",

author = "P Langton and G Hankey and J Eikelboom",

year = "2005",

month = feb,

day = "21",

language = "English",

volume = "182",

pages = "199--199",

journal = "Medical Journal Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Co. Ltd",

number = "4",

}

TY - JOUR

T1 - Cardiovascular safety of rofecoxib (Vioxx)

T2 - lessons learned and unanswered questions

AU - Langton, P

AU - Hankey, G

AU - Eikelboom, J

PY - 2005/2/21

Y1 - 2005/2/21

KW - RANDOMIZED CONTROLLED-TRIALS

KW - ENDOTHELIAL FUNCTION

KW - OSTEOARTHRITIS

KW - INHIBITION

KW - VALDECOXIB

KW - EFFICACY

KW - DISEASE

M3 - Letter

VL - 182

SP - 199

EP - 199

JO - Medical Journal Australia

JF - Medical Journal Australia

SN - 0025-729X

IS - 4

ER -